Navigation Links
AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy

is Conference, Denver, Colorado, November 2-5, 2006, indicated that dosing of Moli1901 for 5 consecutive days by the inhalation route improved lung function in a dose-dependent manner.

About AOP Orphan

AOP Orphan Pharmaceuticals AG is a privately held corporation founded in Vienna in 1997. The company is dedicated to developing, marketing and distributing medicines in niche indications on a Pan-European level with special focus on Central and Eastern Europe, Middle East and Southern Asia.

About Lantibio

Lantibio, Inc. is a development pharmaceutical company focused on discovery, development, and marketing of products for the treatment of ocular disease and serious respiratory conditions. Lantibio's lead product, Moli1901 holds an IND in CF in the US as well as Orphan Drug status in that indication.

This press release might contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from AOP Orphan's and/or Lantibio's expectations and projections. Risks and uncertainties include success of clinical trials for AOP Orphan's and/or Lantibio's products, intellectual property risks, need for additional financing or capital, ability to develop and successfully commercialize our products, ability to enter into licensing agreements, and the ability of the competition to render AOP Orphan's and/or Lantibio's product candidates or technologies obsolete or noncompetitive. AOP Orphan and Lantibio assume no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

CONTACT: Rudolf S. Widmann, CEO of AOP Orphan Pharmaceuticals, +43 1 50372 44, or ; Luis Molina, President-CEO ofLantibio, +1-919-960-0217, or ; Copy Editing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader in ... immunotherapy to treat a variety of cancers, today announced ... BVCF, a China -based healthcare private ... company focused on the development of new therapeutics for ... Shanghai Cancer Institute and Shanghai Renji Hospital, the company ...
(Date:11/26/2014)... -- At the American Dental Association,s Annual Meeting in ... Group was honored to be part of the 2014 ... see and test the Best of Class winners and ... the latest developments in dental technology. This year, featured ... Caries Detection Device and Kerr Demi ™  Ultra ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... Aug. 4 Tolerx, Inc. , a ... and cancer by modulating T cell activity, today announced ... Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment ... research and early-stage product development programs involving novel therapies ...
... Healthcare, Inc. (Nasdaq: GRMH ) will host a conference ... , to discuss the company,s financial results for Q2, 2010. Management will review ... , , , ... be webcast on the investor relations section of Graymark,s website at http://www.graymarkhealthcare.com ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... ISI Telemanagement Solutions, Inc., a leading ... the 2014 Lync Pioneer Award by ... a great honor to ISI, who continues to ... ISI offers an integrated collaboration reporting and recording ... voice, video, Lync IM, and conferencing. , ...
(Date:11/26/2014)... For those with a New Year’s resolution to get in ... at the University of Colorado Anschutz Health and Wellness Center ... 45- 60 minute classes have just started and are included ... memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition and ... fast results , By focusing on low weight loads ...
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... and Drug Administration will have many restaurant chains posting calorie ... movie theater popcorn and ice cream parlor fare. "Americans ... often consuming less nutritious food and underestimating the calories they ... afternoon news conference. Although listing calorie counts on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... , MONDAY, March 28 (HealthDay News) -- Teenagers ... likely to start using marijuana by the time they,re 17, ... birth cohort study that began in 1994 found that by ... and 12 percent of boys had used marijuana or other ...
... San Diego School of Medicine claim that the availability of ... that surgery should become an important part of the primary ... C. Chang, PhD, MPH, MBA, director of Outcomes Research in ... out that surgery in the United States continues to be ...
... ANN ARBOR, Mich. Most women face only a small ... treatment. Yet a new study from the University of Michigan ... speak little English expressed a great deal of worry about ... for some women, these worries can be so strong that ...
... recognizes and neutralizes or destroys toxins and foreign pathogens ... result when the system attacks the body,s own tissues ... sclerosis (MS). MS is a serious condition in which ... spinal cord are destroyed as a result of misdirected ...
... , SUNDAY, March 27 (HealthDay News) -- Baseball ... finds a new study. Researchers analyzed data from more ... and found that pitchers whose teammates were hit by a ... the temperature reached 90 degrees F than on cooler days. ...
... study published today provides a new perspective on the Great ... there were remarkable improvements in life expectancy of over five ... was actually associated with an increase in suicides but reduction ... the current recession in Europe and the U.S. The study, ...
Cached Medicine News:Health News:Surgeon availability tied to survival rate in vehicle crashes 2Health News:Some women worry too much about breast cancer returning, U-M study finds 2Health News:A possible new target for treatment of multiple sclerosis 2Health News:A possible new target for treatment of multiple sclerosis 3Health News:Great Depression did not significantly improve life expectancy in the US 2
... Single Use reloadable linear stapler with ... PI™ disposable stapler is designed for use ... healthy internal tissues. The instrument places a ... when using the 30 VASCULAR cartridges) of ...
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... 75 single-use stapler, anastomotic type, is ... transection, and/or the anastomosis of normal, ... ILA™ 75 single-use stapler, anastomotic type, ... resection, transection, and/or the anastomosis of ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
Medicine Products: